Drug intelligence / Profile preview

IBP-002

Development stage: Preclinical
Lead developer: ImmunoBrain Checkpoint
Administration: Intrathecal

Overview

IBP-002 is a preclinical-stage drug candidate being developed by InBrain Pharma. As of the latest company pipeline updates, the specific therapeutic target, modality, and primary clinical indications for IBP-002 remain undisclosed. The asset is currently positioned in the preclinical phase of development within InBrain Pharma's research portfolio, which also includes IBP-001 (A-Dopamine) for Parkinson's disease.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on IBP-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBP-002.

Explore the full profile